CN101016542A - 一种提高人乳头瘤病毒l1蛋白原核表达产率的方法 - Google Patents
一种提高人乳头瘤病毒l1蛋白原核表达产率的方法 Download PDFInfo
- Publication number
- CN101016542A CN101016542A CN 200710005100 CN200710005100A CN101016542A CN 101016542 A CN101016542 A CN 101016542A CN 200710005100 CN200710005100 CN 200710005100 CN 200710005100 A CN200710005100 A CN 200710005100A CN 101016542 A CN101016542 A CN 101016542A
- Authority
- CN
- China
- Prior art keywords
- nucleotide sequence
- correspondence
- hpv
- albumen
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 25
- 108700005307 Human papillomavirus HPV L1 Proteins 0.000 title claims abstract description 7
- 108020004705 Codon Proteins 0.000 claims abstract description 74
- 229960005486 vaccine Drugs 0.000 claims abstract description 15
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 11
- 239000002773 nucleotide Substances 0.000 claims description 84
- 125000003729 nucleotide group Chemical group 0.000 claims description 84
- 229920000642 polymer Polymers 0.000 claims description 22
- 241000700605 Viruses Species 0.000 claims description 14
- 230000008521 reorganization Effects 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000780272 Mammilla Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 108700010070 Codon Usage Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 15
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 241000701806 Human papillomavirus Species 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 101000641175 Human papillomavirus type 18 Major capsid protein L1 Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 108700042300 human papillomavirus type 52 L1 Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 102000029301 Protein S Human genes 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021432 Immunisation reaction Diseases 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000021145 human papilloma virus infection Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
HPV型 | 密码子优化序列表达得到的L1蛋白占总蛋白的百分比(%) | 未经密码子优化的序列表达得到的L1蛋白占总蛋白的百分比(%) |
HPV6 | 22.3 | 6.1 |
HPV11 | 21.1 | 7.2 |
HPV18 | 19.8 | 6.5 |
HPV31 | 24.6 | 7.9 |
HPV33 | 26.9 | 8.1 |
HPV35 | 22.0 | 6.6 |
HPV39 | 22.4 | 5.8 |
HPV45 | 20.7 | 7.8 |
HPV51 | 26.6 | 8.5 |
HPV52 | 20.8 | 5.7 |
HPV56 | 23.7 | 6.3 |
HPV58 | 24.5 | 6.7 |
HPV59 | 22.3 | 7.2 |
HPV68 | 22.5 | 6.9 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100051003A CN100532548C (zh) | 2007-02-14 | 2007-02-14 | 一种提高人乳头瘤病毒l1蛋白原核表达产率的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100051003A CN100532548C (zh) | 2007-02-14 | 2007-02-14 | 一种提高人乳头瘤病毒l1蛋白原核表达产率的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101016542A true CN101016542A (zh) | 2007-08-15 |
CN100532548C CN100532548C (zh) | 2009-08-26 |
Family
ID=38725763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007100051003A Active CN100532548C (zh) | 2007-02-14 | 2007-02-14 | 一种提高人乳头瘤病毒l1蛋白原核表达产率的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100532548C (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102459317A (zh) * | 2009-06-25 | 2012-05-16 | 大型界面系统校际研究中心 | 用于crm197及其衍生物的生产的人工基因的细菌表达 |
CN103740728A (zh) * | 2013-12-30 | 2014-04-23 | 中国人民武装警察部队后勤学院 | 稀有密码子改造的人znf580基因及该基因原核表达的蛋白及多克隆抗体 |
CN104761623A (zh) * | 2013-12-17 | 2015-07-08 | 北京康乐卫士生物技术股份有限公司 | 一种以α-螺旋5为靶标的抑制HPV L1五聚体形成的抑制剂 |
CN104962567A (zh) * | 2013-12-03 | 2015-10-07 | 北京康乐卫士生物技术股份有限公司 | 6型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN105585631A (zh) * | 2014-11-12 | 2016-05-18 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒16型单克隆抗体及其应用 |
CN105713087A (zh) * | 2014-11-12 | 2016-06-29 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒58型单克隆抗体及其应用 |
CN106399329A (zh) * | 2015-08-12 | 2017-02-15 | 北京康乐卫士生物技术股份有限公司 | 33型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701797A (zh) * | 2015-08-12 | 2017-05-24 | 北京康乐卫士生物技术股份有限公司 | 31型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701798A (zh) * | 2015-08-12 | 2017-05-24 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701796A (zh) * | 2015-08-12 | 2017-05-24 | 北京康乐卫士生物技术股份有限公司 | 52型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN113073105A (zh) * | 2021-03-23 | 2021-07-06 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
CN115960178A (zh) * | 2022-12-28 | 2023-04-14 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒hpv59 l1蛋白的表达和类病毒样颗粒及其制备方法 |
CN116023446A (zh) * | 2022-10-28 | 2023-04-28 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒hpv68 l1蛋白的表达和类病毒样颗粒及其制备方法 |
CN117054647A (zh) * | 2023-07-17 | 2023-11-14 | 广东省一鼎生物技术有限公司 | 一种检测HPV IgG抗体试剂盒及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115766B (zh) * | 2004-06-18 | 2013-05-08 | 印度免疫有限公司 | 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1 |
-
2007
- 2007-02-14 CN CNB2007100051003A patent/CN100532548C/zh active Active
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102459317A (zh) * | 2009-06-25 | 2012-05-16 | 大型界面系统校际研究中心 | 用于crm197及其衍生物的生产的人工基因的细菌表达 |
CN105002190B (zh) * | 2013-12-03 | 2022-11-08 | 北京康乐卫士生物技术股份有限公司 | 11型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN104962567B (zh) * | 2013-12-03 | 2022-11-08 | 北京康乐卫士生物技术股份有限公司 | 6型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN104962567A (zh) * | 2013-12-03 | 2015-10-07 | 北京康乐卫士生物技术股份有限公司 | 6型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN105002190A (zh) * | 2013-12-03 | 2015-10-28 | 北京康乐卫士生物技术股份有限公司 | 11型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN105039358A (zh) * | 2013-12-03 | 2015-11-11 | 北京康乐卫士生物技术股份有限公司 | 58型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN105039359A (zh) * | 2013-12-03 | 2015-11-11 | 北京康乐卫士生物技术股份有限公司 | 16型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN105177025B (zh) * | 2013-12-03 | 2022-11-01 | 北京康乐卫士生物技术股份有限公司 | 18型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN105177025A (zh) * | 2013-12-03 | 2015-12-23 | 北京康乐卫士生物技术股份有限公司 | 18型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN104761623A (zh) * | 2013-12-17 | 2015-07-08 | 北京康乐卫士生物技术股份有限公司 | 一种以α-螺旋5为靶标的抑制HPV L1五聚体形成的抑制剂 |
CN104761623B (zh) * | 2013-12-17 | 2019-11-29 | 北京康乐卫士生物技术股份有限公司 | 一种以α-螺旋5为靶标的抑制HPV L1五聚体形成的抑制剂 |
CN103740728B (zh) * | 2013-12-30 | 2016-08-17 | 中国人民武装警察部队后勤学院 | 稀有密码子改造的人znf580基因及该基因原核表达的蛋白及多克隆抗体 |
CN103740728A (zh) * | 2013-12-30 | 2014-04-23 | 中国人民武装警察部队后勤学院 | 稀有密码子改造的人znf580基因及该基因原核表达的蛋白及多克隆抗体 |
CN105713087A (zh) * | 2014-11-12 | 2016-06-29 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒58型单克隆抗体及其应用 |
CN105585631A (zh) * | 2014-11-12 | 2016-05-18 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒16型单克隆抗体及其应用 |
CN105713087B (zh) * | 2014-11-12 | 2020-05-08 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒58型单克隆抗体及其应用 |
CN106701796A (zh) * | 2015-08-12 | 2017-05-24 | 北京康乐卫士生物技术股份有限公司 | 52型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701797A (zh) * | 2015-08-12 | 2017-05-24 | 北京康乐卫士生物技术股份有限公司 | 31型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701797B (zh) * | 2015-08-12 | 2021-06-15 | 北京康乐卫士生物技术股份有限公司 | 31型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106399329A (zh) * | 2015-08-12 | 2017-02-15 | 北京康乐卫士生物技术股份有限公司 | 33型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701798B (zh) * | 2015-08-12 | 2021-09-17 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701796B (zh) * | 2015-08-12 | 2021-11-16 | 北京康乐卫士生物技术股份有限公司 | 52型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106701798A (zh) * | 2015-08-12 | 2017-05-24 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN106399329B (zh) * | 2015-08-12 | 2021-06-11 | 北京康乐卫士生物技术股份有限公司 | 33型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
CN113073105A (zh) * | 2021-03-23 | 2021-07-06 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
CN116023446A (zh) * | 2022-10-28 | 2023-04-28 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒hpv68 l1蛋白的表达和类病毒样颗粒及其制备方法 |
CN115960178A (zh) * | 2022-12-28 | 2023-04-14 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒hpv59 l1蛋白的表达和类病毒样颗粒及其制备方法 |
CN115960178B (zh) * | 2022-12-28 | 2023-09-08 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒hpv59 l1蛋白的表达和类病毒样颗粒及其制备方法 |
WO2024140162A1 (zh) * | 2022-12-28 | 2024-07-04 | 北京康乐卫士生物技术股份有限公司 | 人乳头瘤病毒hpv59 l1蛋白的表达和类病毒样颗粒及其制备方法 |
CN117054647A (zh) * | 2023-07-17 | 2023-11-14 | 广东省一鼎生物技术有限公司 | 一种检测HPV IgG抗体试剂盒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100532548C (zh) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100532548C (zh) | 一种提高人乳头瘤病毒l1蛋白原核表达产率的方法 | |
CN101245099A (zh) | 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用 | |
CN1942583B (zh) | Hpv58l1在酵母中的最优化表达 | |
US7700103B2 (en) | Optimized expression of HPV 52 L1 in yeast | |
US7482015B2 (en) | Optimized expression of HPV 45 L1 in yeast | |
CN101481408A (zh) | 防止高度聚合的重组人乳头瘤病毒l1蛋白的修饰序列 | |
CN101481407A (zh) | 重组人乳头瘤病毒l1衣壳蛋白的修饰序列 | |
CN114127098B (zh) | 嵌合的人乳头瘤病毒51型l1蛋白 | |
WO2021013073A1 (zh) | 嵌合的乳头瘤病毒l1蛋白 | |
CN1293093C (zh) | 乳头瘤病毒衣壳蛋白的原核制备和应用 | |
CN114127097B (zh) | 嵌合的人乳头瘤病毒56型l1蛋白 | |
CN114127127B (zh) | 嵌合的人乳头瘤病毒35型l1蛋白 | |
CN114127100B (zh) | 嵌合的人乳头瘤病毒39型l1蛋白 | |
CN103992395A (zh) | 重组hpv-58型l1的vlp疫苗及其制备方法 | |
CN103819543A (zh) | 重组的人乳头瘤病毒6型l1蛋白及其用途 | |
WO2021013062A1 (zh) | 嵌合的人乳头瘤病毒31型l1蛋白 | |
CN104045696A (zh) | 重组的人乳头瘤病毒16型l1蛋白及其用途 | |
CN104045695A (zh) | 重组的人乳头瘤病毒18型l1蛋白及其用途 | |
MXPA06005306A (en) | Optimized expression of hpv 58 l1 in yeast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING HEALTHY GUARD BIOTECHNOLOGY INC. Free format text: FORMER OWNER: MA RUNLIN Effective date: 20130312 Free format text: FORMER OWNER: CHEN XIAOJIANG Effective date: 20130312 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100107 CHAOYANG, BEIJING TO: 100176 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130312 Address after: Longsheng industrial park, 7 No. 100176 Beijing Rongchang economic and Technological Development Zone Street No. 2 building 201 unit Patentee after: Beijing Healthy Guard Biotechnology Inc. Address before: 100107 Beijing city Chaoyang District Wankexingyuan 9 room No. 1505 Patentee before: Ma Runlin Patentee before: Chen Xiaojiang |
|
DD01 | Delivery of document by public notice |
Addressee: Ma Runlin Document name: Notification of Passing Examination on Formalities |
|
C56 | Change in the name or address of the patentee |
Owner name: BEIJING HEALTH GUARD BIOTECHNOLOGY CO., LTD. Free format text: FORMER NAME: BEIJING HEALTHY GUARD BIOTECHNOLOGY INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Longsheng industrial park, 7 No. 100176 Beijing Rongchang economic and Technological Development Zone Street No. 2 building 201 unit Patentee after: Beijing Health Guard Biotechnology Co., Ltd. Address before: Longsheng industrial park, 7 No. 100176 Beijing Rongchang economic and Technological Development Zone Street No. 2 building 201 unit Patentee before: Beijing Healthy Guard Biotechnology Inc. |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ma Runlin Inventor after: Chen Xiaojiang Inventor after: Liu Yongjiang Inventor before: Ma Runlin Inventor before: Chen Xiaojiang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MA RUNLIN CHEN XIAOJIANG TO: MA RUNLIN CHEN XIAOJIANG LIU YONGJIANG |